# SRTD Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/srtd-biotech

- Industry: Biotechnology
- Headquarters: Julich, Germany
- Website: www.srtd-biotech.com/
- Latest round: Seed (Nov 14, 2024)
- Investors on record: 1

## About

Based in Julich, Germany, and founded in 2023 by co-founder Dr. Bernd Hoffmann (CEO) and Dr. Heribert Bohlen, SRTD Biotech GmbH is focused on developing RNA-based therapies to improve treatment efficacy for various diseases such as primary liver cancer and glioblastoma, utilizing selectively expressed RNAs for targeted therapeutic delivery. In November 2024, SRTD Biotech GmbH raised an undisclosed amount in seed funding led by High-Tech Gründerfonds.

SRTD Biotech specializes in the development of selectively expressed RNAs (seRNAs), an advanced RNA-based therapeutic approach intended to improve treatment efficacy for diseases with high medical need, such as primary liver cancer (HCC) and glioblastoma. The core product offering is the seRNA technology, which enables cell-specific targeting and therapeutic delivery, thereby minimizing side effects and improving treatment outcomes. The seRNA platform is intended to activate only in diseased cells, sparing healthy tissue, and is employed in strategies to eliminate virally infected cells. SRTD Biotech is focused on advancing seRNA applications through rigorous preclinical studies, demonstrating significant effectiveness and biocompatibility in animal models.

Revenue generation for SRTD Biotech is anticipated through strategic partnerships with healthcare providers, research institutions, and possibly biopharmaceutical companies interested in licensing seRNA technology for clinical applications.

## Funding rounds

- Seed, Nov 14, 2024 — High-Tech Gruenderfonds

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed